• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    10/17/24 12:47:11 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRNX alert in real time by email
    SC 13G/A 1 Crinetics_Pharma_Inc.htm SCHEDULE 13G Amendment No. 15

     

      SECURITIES AND EXCHANGE COMMISSION  
      Washington, D.C. 20549  
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. )*
     

    CRINETICS PHARMACEUTICALS INC

    (Name of Issuer)
     

    COMMON STOCK

    (Title of Class of Securities)
     

    22663K107

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 5 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

     

    22663K107 13G Page 2 of 5 Pages

     

    1

    NAME OF REPORTING PERSON

    STATE STREET CORPORATION

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    MA

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    2,583,040

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    2,838,484

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,838,484.00

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.6%

    12

    TYPE OF REPORTING PERSON

    HC

             

     

     

     

    22663K107 13G Page 3 of 5 Pages

     

    Item 1(a). NAME OF ISSUER
       
      CRINETICS PHARMACEUTICALS INC

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
       
      10222 BARNES CANYON ROAD BUILDING 2 SAN DIEGO CA 92121 UNITED STATES

     

    Item 2(a). NAME OF PERSON FILING
       
     

    STATE STREET CORPORATION

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

     

    Item 2(c). CITIZENSHIP
       
      MA

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      COMMON STOCK

     

    Item 2(e). CUSIP NUMBER
       
      22663K107

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

    STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
      (b) Bank as defined in Section 3(a)(6) of the Act;
      (c) Insurance company as defined in Section 3(a)(19) of the Act;
      (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
      (f)

    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     

      (g) X

    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

     

      (h)

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i)

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
      (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

     

    22663K107 13G Page 4 of 5 Pages

     

    Item 4. OWNERSHIP
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
      (a) Amount beneficially owned: 2,838,484.00  
      (b) Percent of class: 3.6%  
      (c) Number of shares as to which the person has:    
             
        (i) Sole power to vote or to direct the vote: 0
        (ii) Shared power to vote or to direct the vote 2,583,040
        (iii) Sole power to dispose or to direct the disposition of 0
        (iv) Shared power to dispose or to direct the disposition of 2,838,484
             
      Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
      ý
      Instruction: Dissolution of a group requires a response to this item.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      NOT APPLICABLE

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      NOT APPLICABLE

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      NOT APPLICABLE

     

    Item 10. CERTIFICATION

     

      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
       

     

     

     

    22663K107 13G Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: October 14, 2024

     

       
         
         
        ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
         
         

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    Get the next $CRNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRNX

    DatePrice TargetRatingAnalyst
    7/2/2026$55.00Buy
    UBS
    1/12/2026$67.00Neutral → Buy
    Goldman
    7/10/2025$36.00Neutral
    Goldman
    3/25/2025$60.00Buy
    Stifel
    2/11/2025Buy
    TD Cowen
    2/4/2025Peer Perform
    Wolfe Research
    1/22/2025$55.00Hold → Buy
    Jefferies
    3/6/2024$68.00Buy
    Citigroup
    More analyst ratings

    $CRNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Vivaldi Coelho Rogerio sold $120,000 worth of shares (3,000 units at $40.00) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 19,225 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    7/7/26 4:30:37 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Deardorf Caren was granted 5,925 shares, increasing direct ownership by 36% to 22,225 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    6/22/26 5:09:54 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fust Matthew K was granted 5,925 shares, increasing direct ownership by 26% to 28,761 units (SEC Form 4)

    4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)

    6/22/26 5:05:47 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    SEC Filings

    View All

    SEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.

    DEFA14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    7/10/26 4:03:03 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement

    8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    7/10/26 4:01:22 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.

    DEFA14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)

    7/6/26 5:24:17 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Crinetics Pharmaceuticals with a new price target

    UBS initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $55.00

    7/2/26 8:15:40 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals upgraded by Goldman with a new price target

    Goldman upgraded Crinetics Pharmaceuticals from Neutral to Buy and set a new price target of $67.00

    1/12/26 7:47:46 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Crinetics Pharmaceuticals with a new price target

    Goldman initiated coverage of Crinetics Pharmaceuticals with a rating of Neutral and set a new price target of $36.00

    7/10/25 8:53:33 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vertex to Acquire Crinetics Pharmaceuticals

    - Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated ther

    7/6/26 4:04:00 PM ET
    $VRTX
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

    SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Tuesday, August 4 at 4:30 p.m. ET Domestic:1 833-461-5787International:1 585-542-9983Meeting ID:758613006Passcode:214866   Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is re

    6/30/26 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

    Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New results from the Phase 1b/2a ACTH-dependent Cushing's syndrome trial also presented, showing atumelnant rapidly lowered early morning cortisol and normalized urinary free cortisol levels even at lower dose SAN DIEGO, June 14, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented data today from the open-label, Phase 2 congenital adrenal hyperplasia (CAH) adult study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antag

    6/14/26 4:30:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 7:55:29 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Crinetics Pharmaceuticals Inc.

    SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 5:46:54 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Crinetics Pharmaceuticals Inc.

    SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)

    11/14/24 1:22:38 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Financials

    Live finance-specific insights

    View All

    Vertex to Acquire Crinetics Pharmaceuticals

    - Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated ther

    7/6/26 4:04:00 PM ET
    $VRTX
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026

    SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Tuesday, August 4 at 4:30 p.m. ET Domestic:1 833-461-5787International:1 585-542-9983Meeting ID:758613006Passcode:214866   Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is re

    6/30/26 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

          PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter       Management Hosting Conference Call at 4:30 p.m. ET Today         SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2026. "We are extremely pleased with the significant impact that Palsonify is making across the community. This is illustrated by the strong adoption of Pa

    5/7/26 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRNX
    Leadership Updates

    Live Leadership Updates

    View All

    Crinetics and Leading Patient Groups Launch 'Everyday Advocacy' Initiative to Empower People Across Endocrine Disease Communities

    Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the launch of Everyday Advocacy, a new initiative designed to support patient education, self-advocacy, and connection within endocrine disease communities. "Crinetics is led by a conviction that meaningful progress for endocrine disease treatment begins

    6/2/26 4:05:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer

    Ms. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Neutrolis Inc. a clinical-stage biotechnology company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Caren Deardorf as Chief Business & Strategy Officer (CBSO). Ms. Deardorf will lead corporate and pipeline strategy, business development, and early commercial strategy as the company advances its clinical pipeline. Ms. Dear

    4/15/26 2:00:00 PM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer

    SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti

    2/24/25 8:30:00 AM ET
    $CRNX
    Biotechnology: Pharmaceutical Preparations
    Health Care